Sugi Predict

Sugi Predict / Compounds / SCHEMBL1764375

SCHEMBL1764375

SCHEMBL1764375

COc1ccc2c(c1)CCC(=O)N2

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 2/20 0.65
▸ CYP1A2 P05177 2/20 0.64
▸ CYP3A4 P08684 2/20 0.64
▸ CYP2C19 P33261 1/20 0.64
▸ ALDH1A1 P00352 2/20 0.63
▸ CYP11B1 P15538 1/20 0.62
▸ CYP11B2 P19099 1/20 0.62
▸ PDE3B Q13370 2/20 0.59
▸ PDE3A Q14432 2/20 0.59
▸ MAOA P21397 6/20 0.58
▸ MAOB P27338 6/20 0.58
▸ CRBN Q96SW2 2/20 0.55
▸ KIF11 P52732 1/20 0.55
▸ CYP2C9 P11712 1/20 0.52
▸ POLB P06746 1/20 0.51
▸ MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28978962 0.90 PDE3B (0.56) PKMCYP1A2CYP3A4CYP2C19ALDH1A1
SCHEMBL3186685 0.90 PDE3B (0.56) PKMCYP1A2CYP3A4CYP2C19ALDH1A1
SCHEMBL8994250 0.87 PDE3B (0.59) PKMCYP1A2CYP3A4CYP2C19ALDH1A1
SCHEMBL703728 0.86 MAOB (0.58) CYP1A2CYP11B1CYP11B2PDE3BPDE3A
SCHEMBL29724095 0.86 MAOB (0.58) CYP1A2CYP11B1CYP11B2PDE3BPDE3A
SCHEMBL4820998 0.84 MAOB (0.76) PKMCYP1A2CYP3A4CYP2C19ALDH1A1
SCHEMBL20214 0.84 PDE3B (0.66) PKMALDH1A1PDE3BPDE3AMAOA
SCHEMBL31040124 0.84 PDE3B (0.66) PKMALDH1A1PDE3BPDE3AMAOA
SCHEMBL24314993 0.84 CYP1A2 (0.70) PKMCYP1A2CYP3A4CYP2C19ALDH1A1
SCHEMBL15387004 0.83 MAOA (0.58) PKMCYP1A2CYP3A4CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4561561-A2 SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR Septerna, Inc. (US) 2025-06-04 — — EP disclosed
CN-119241548-A Dihydropteridinone derivatives containing fused benzene rings and use thereof 沈阳药科大学 2025-01-03 — — CN disclosed
CN-111587239-B Method for producing lactam compound and lactam compound produced by the method 基础科学研究院 2024-04-02 — — CN disclosed
WO-2024026076-A2 SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR SEPTERNA, INC. (US) 2024-02-01 — — WO disclosed
CN-115141141-A Nitrogen-containing heterocyclic derivative with acrylate structure and preparation method thereof 吉林大学 2022-10-04 — — CN disclosed
US-11186589-B2 Cyanoindoline derivatives as NIK inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-11-30 — — US disclosed
CN-107793413-B Pyrimidine heterocyclic compound and preparation method and application thereof 上海科州药物研发有限公司 2021-09-28 — — CN disclosed
US-11046661-B2 Method for producing lactam compound, and lactam compound produced thereby INSTITUTE FOR BASIC SCIENCE (KR) 2021-06-29 — — US disclosed
US-11046661-B2 Method for producing lactam compound, and lactam compound produced thereby INSTITUTE FOR BASIC SCIENCE (KR) 2021-06-29 — — US disclosed
US-20210032267-A1 CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-02-04 — — US disclosed
EP-0824100-B1 Piperidinylamino tricyclic compouds as substance P antagonists PFIZER (US) 2000-09-20 — — EP disclosed
US-5972930-A TREATING GASTROINTESTINAL DISORDER, A CENTRAL NERVOUS SYSTEM DISORDER, AN INFLAMMATORY DISEASE, EMESIS, URINARY INCONTINENCE, PAIN, MIGRAINE, SUNBURN, ANGIOGENESIS, DISEASES CAUSED BY HELICOBACTER PYLORI PFIZER, INC. (US) 1999-10-26 — — US disclosed
EP-0840732-A1 SUBSTITUTED BENZOLACTAM COMPOUNDS AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1998-05-13 — — EP disclosed
EP-0824100-A1 Piperidinylamino tricyclic compouds as substance P antagonists PFIZER INC. (US) 1998-02-18 — — EP disclosed
US-5639770-A SUPEROXIDE INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-06-17 — — US disclosed
WO-1997003066-A1 SUBSTITUTED BENZOLACTAM COMPOUNDS AS SUBSTANCE P ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 1997-01-30 — — WO disclosed
EP-0600092-A1 THIAZOLE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-06-08 — — EP disclosed
US-4058532-A 1-Phenyl-3,4-dihydrocarbostyrils STERLING DRUG INC. (US) 1977-11-15 — — US disclosed
US-4049715-A 3-[2-(4-Anisidino)phenyl]-1-phenyl-1-propiophenones and propanols STERLING DRUG INC. (US) 1977-09-20 — — US disclosed
US-3994902-A Certain 1,2-diphenyl-1,2,3,4-tetrahydroquinoline compounds STERLING DRUG INC. (US) 1976-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210032267-A1 CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS MAP3K14, NFKBIA, MAP3K15 PKM 1072/4885CYP1A2 3160/4885CYP3A4 4079/4885
US-11046661-B2 Method for producing lactam compound, and lactam compound produced thereby SQLE, COASY, DHPS PKM 2748/4885CYP1A2 173/4885CYP3A4 71/4885
US-11186589-B2 Cyanoindoline derivatives as NIK inhibitors MAP3K14, NFKBIA, MAP3K15 PKM 1072/4885CYP1A2 3160/4885CYP3A4 4079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.